The study, which appeared in the Journal for ImmunoTherapy of Cancer, suggests that IO112 could enhance anti-tumor immunity by reprogramming tumor-associated macrophages (TAMs) and promoting a ...

Io Biotech Aps has presented preclinical data regarding their Arg1-derived peptide cancer vaccine IO-112 as a potential immunotherapeutic that would allow controlling the tumor microenvironment.